| Patient | Emile Griffith |
|---|---|
| Date of birth | 1959-02-03 |
| Identifiers | MRN HR-BX005-SYN; SSN (made up) 000-05-6418 |
| Document date | 2026-11-01 |
| Author | Celeste Fairbanks-Ochieng, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing care with his care partner for memory loss and confusion: cognitive testing, reversible causes, PTSD and depression screening with a safety assessment, falls, and the plan. Concerns: He wants to know why he forgets things and wants to keep living at home; He still dreams about the fight in which his opponent died and wants the nightmares to ease; His care partner worries about him getting lost and about managing as things change. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 25 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-05-05 to 2026-06-16 | completed | S |
| Sertraline 50 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-06-16 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| MRI of the brain without contrast, with susceptibility-weighted imaging: mild generalized atrophy, slightly more in the frontal lobes, with hippocampi in the normal range for age (medial temporal atrophy score 1 on each side); a small area of old injury (encephalomalacia with hemosiderin) at the tip of the right frontal lobe; seven microbleeds at the gray-white junction of both frontal lobes; a few small white matter hyperintensities (Fazekas 1); a cavum septi pellucidi; no infarct, mass, subdural collection or hydrocephalus | 2026-05-19 to 2026-05-19 | completed | S |
| Neuropsychological testing, about three hours with breaks: slowed processing speed and reduced attention, set-shifting and verbal fluency; learning and free recall reduced but much better with cues and recognition (a retrieval pattern rather than rapid forgetting); naming, language and visual perception intact; consistent with mild cognitive impairment of frontal-subcortical type; effort measures valid; mood and PTSD symptoms noted as contributors | 2026-06-10 to 2026-06-10 | completed | S |
| Cognitive processing therapy for PTSD with the clinic psychologist: twelve weekly sessions, adapted for memory problems (shorter sessions, written one-page summaries, phone reminders, and his care partner helping with practice between sessions, with his consent) | 2026-05-26 to 2026-08-11 | completed | S |
| Advance care planning conversation, about 30 minutes, with him and his care partner; his capacity to name a health care agent and state his values was assessed and present | 2026-08-04 to 2026-08-04 | completed | S |
| Physical therapy for balance and strength: ten sessions with a home exercise program (sit-to-stand, heel raises, tandem stance, walking program) | 2026-06-23 to 2026-09-01 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-14 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2026-08-04 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-08-04 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-10-27 | High-dose influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-27 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1958 to 1977 | Professional boxing from 1958 to 1977, 112 bouts over nineteen years: long exposure to repetitive head impacts; no source read records a count of knockouts or losses of consciousness | D (CLM-0002, CLM-0003) |
| March 24, 1962 | Title fight in 1962 after which his opponent died ten days later; lifelong nightmares and distress about it, in his own public words | D (CLM-0004, CLM-0005) |
| 1992 | Severe beating by a group of men in 1992, one with a baseball bat, with several months in hospital, much of it in intensive care; short-term memory problems reported since | D (CLM-0008, CLM-0009) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He wants to know why he forgets things and wants to keep living at home | active | S |
| He still dreams about the fight in which his opponent died and wants the nightmares to ease | active | S |
| His care partner worries about him getting lost and about managing as things change | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 6.1 on 2026-05-05; Hemoglobin [Mass/volume] in Blood 14.2 on 2026-05-05; Platelets [#/volume] in Blood by Automated count 228 on 2026-05-05; Sodium [Moles/volume] in Serum or Plasma 137 on 2026-09-15; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-05-05; Creatinine [Mass/volume] in Serum or Plasma 1 on 2026-05-05; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 82 on 2026-05-05; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-05-05; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-05-05; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 418 on 2026-05-05; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 2026-05-05; Total score [MoCA] 22 on 2026-05-05; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-08-04; PC-PTSD-5 score [PC-PTSD-5] 4 on 2026-05-05; PTSD PCL-5 score [PCL-5] 20 on 2026-10-27; Clinical Dementia Rating scale [CDR] 0.5 on 2026-05-19; Total score [AUDIT-C] 2 on 2026-08-04; Cholesterol [Mass/volume] in Serum or Plasma 186 on 2026-08-04; Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 on 2026-08-04; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 112 on 2026-08-04; Triglyceride [Mass/volume] in Serum or Plasma 110 on 2026-08-04; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-08-04 [S]
Strengths and supports: Strengths and supports: warmth, humor and generosity, pride in his career and in the fighters he trained, his care partner, family on the islands and in New York, and friends from boxing [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Memory loss and confusion over about a year, worse in recent months, reported by him and his care partner: repeating stories and questions, losing the thread of conversations, mixing up days, two missed appointments, and once getting lost changing trains on a familiar route; cause to be found | resolved | confirmed | R41.3 | S — Synthetic presenting problem anchored to the documented short-term memory problems; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age. |
| Post-traumatic stress disorder, chronic, after two index events (a title fight decades ago after which his opponent died, and a severe assault thirteen years ago): nightmares, unwanted images, avoidance of fight footage, guilt and self-blame, being on guard in crowds, poor sleep; PCL-5 41 | active | confirmed | F43.12 | S — Synthetic modern diagnosis at intake by clinical interview against DSM-5-TR criteria, anchored to his public words about lifelong nightmares; not a historical diagnosis. |
| Mild cognitive impairment (mild neurocognitive disorder) with slowed processing, executive and memory-retrieval deficits, most likely due to traumatic brain injury from a nineteen-year professional boxing career and a severe assault; meets the NINDS research criteria for traumatic encephalopathy syndrome (a research diagnosis); Alzheimer's disease co-pathology not excluded | active | confirmed | G31.84 | S — Synthetic modern diagnosis at the third visit after MRI and neuropsychological testing; anchored to the documented memory problems and pugilistic dementia, not a retrospective diagnosis of his real illness. |
| Personal history of traumatic brain injury: repetitive head impacts over 112 professional bouts, and a severe head injury in an assault thirteen years ago with months in hospital | active | confirmed | Z87.820 | S — Synthetic coding of the documented career and assault. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-05 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-05 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-05-05 | Platelets [#/volume] in Blood by Automated count | 228 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-05 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-05 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-05 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-05-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 82 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-05 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-140 mg/dL | Normal | S |
| 2026-05-05 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-05-05 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 418 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-05-05 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-05-05 | Total score [MoCA] | 22 | {score} | S | ||
| 2026-05-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-05-05 | PC-PTSD-5 score [PC-PTSD-5] | 4 | {score} | S | ||
| 2026-05-05 | PTSD PCL-5 score [PCL-5] | 41 | {score} | S | ||
| 2026-05-19 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-19 | Clinical Dementia Rating scale [CDR] | 0.5 | {score} | S | ||
| 2026-06-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-06-16 | PTSD PCL-5 score [PCL-5] | 37 | {score} | S | ||
| 2026-09-15 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-09-15 | PTSD PCL-5 score [PCL-5] | 26 | {score} | S | ||
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-10-27 | PTSD PCL-5 score [PCL-5] | 20 | {score} | S | ||
| 2026-08-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-08-04 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-08-04 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-08-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-08-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 112 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-08-04 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-04 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-05 | Body height | 170 | cm | S |
| 2026-05-05 | Body weight | 74 | kg | S |
| 2026-05-05 | Body mass index (BMI) [Ratio] | 25.6 | kg/m2 | S |
| 2026-05-05 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-05-05 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-05-05 | Heart rate | 70 | /min | S |
| 2026-05-05 | Respiratory rate | 14 | /min | S |
| 2026-05-05 | Body temperature | 36.7 | Cel | S |
| 2026-05-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-19 | Body height | 170 | cm | S |
| 2026-05-19 | Body weight | 73.8 | kg | S |
| 2026-05-19 | Body mass index (BMI) [Ratio] | 25.5 | kg/m2 | S |
| 2026-05-19 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-05-19 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-19 | Heart rate | 68 | /min | S |
| 2026-05-19 | Respiratory rate | 14 | /min | S |
| 2026-05-19 | Body temperature | 36.6 | Cel | S |
| 2026-05-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-16 | Body height | 170 | cm | S |
| 2026-06-16 | Body weight | 73.6 | kg | S |
| 2026-06-16 | Body mass index (BMI) [Ratio] | 25.5 | kg/m2 | S |
| 2026-06-16 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-06-16 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-16 | Heart rate | 68 | /min | S |
| 2026-06-16 | Respiratory rate | 14 | /min | S |
| 2026-06-16 | Body temperature | 36.6 | Cel | S |
| 2026-06-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-15 | Body height | 170 | cm | S |
| 2026-09-15 | Body weight | 73.9 | kg | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 25.6 | kg/m2 | S |
| 2026-09-15 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-09-15 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-15 | Heart rate | 66 | /min | S |
| 2026-09-15 | Respiratory rate | 14 | /min | S |
| 2026-09-15 | Body temperature | 36.7 | Cel | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-27 | Body height | 170 | cm | S |
| 2026-10-27 | Body weight | 74.2 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 25.7 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 66 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-04 | Body height | 170 | cm | S |
| 2026-08-04 | Body weight | 73.8 | kg | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 25.5 | kg/m2 | S |
| 2026-08-04 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-08-04 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-04 | Heart rate | 66 | /min | S |
| 2026-08-04 | Respiratory rate | 14 | /min | S |
| 2026-08-04 | Body temperature | 36.6 | Cel | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-05-05 | Establishing care with his care partner for memory loss and confusion: cognitive testing, reversible causes, PTSD and depression screening with a safety assessment, falls, and the plan | finished | S |
| 2026-05-19 | Two-week review, seen the same day by cognitive neurology: brain MRI, staging, traumatic encephalopathy syndrome and other causes, sertraline and sodium | finished | S |
| 2026-06-16 | Six-week review: neuropsychological testing, the diagnosis and the plan, PTSD treatment, safety and caregiver support | finished | S |
| 2026-09-15 | Four-month review: PTSD after cognitive processing therapy, mood, sodium, falls and caregiver strain | finished | S |
| 2026-10-27 | Six-month review: PTSD, mood, cognition, safety and the plan for the year ahead | finished | S |
| 2026-08-04 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Cognitive work-up under the Alzheimer's Association guideline: history from him and his care partner, MoCA, function, depression and PTSD screening, first-tier blood tests (blood count, metabolic panel, B12, TSH), a medicine review for anticholinergic and sedating drugs, a sleep apnea screen, hearing and vision checks, and brain MRI | completed | GL-ALZ-2024, GL-ALZ-PC-2024, GL-CMID-2026 | S |
| Cognitive neurology consultation at the memory clinic to stage the impairment, weigh traumatic brain injury, traumatic encephalopathy syndrome, Alzheimer's disease, vascular disease and the effects of PTSD and depression, and choose further testing | completed | GL-ALZ-2024, GL-TES-2021 | S |
| PTSD treatment by shared decision: cognitive processing therapy with the clinic psychologist, weekly for about twelve sessions, adapted for memory problems; and sertraline 25 mg each morning, raised to 50 mg after four to six weeks if tolerated, with sodium checked two weeks after starting and after the increase; benzodiazepines avoided | completed | GL-PTSD-2023, GL-BEERS-2023 | S |
| Collaborative safety plan with warning signs, coping steps, people to call, the clinic number and the 988 Suicide & Crisis Lifeline; medicines kept by his care partner; PHQ-9 item 9 and safety reviewed at every visit | completed | GL-SUICIDE-2024, GL-PTSD-2023 | S |
| Falls: STEADI assessment, physical therapy for balance and strength with a home program, and a home safety check | completed | GL-STEADI, GL-CMID-2026 | S |
| Measurement-based care: PCL-5 and PHQ-9 at each chronic-care visit during treatment; MoCA yearly or sooner with change; medicine review every visit | completed | GL-PTSD-2023, GL-CMID-2026, GL-ALZ-2024 | S |
| After the diagnosis: no cholinesterase inhibitor or memantine, which are not shown to help mild cognitive impairment or traumatic brain injury; memory strategies (one calendar, phone reminders, a fixed daily routine), exercise, social activity, sleep and blood pressure care; repeat neuropsychological testing in twelve to eighteen months or sooner with change; Alzheimer's disease biomarker testing explained and declined for now, as it would not change his care | completed | GL-ALZ-2024, GL-TES-2021, GL-CMID-2026 | S |
| Travel and money safety: carry a card with his address and his care partner's number, share his phone location, travel with company on unfamiliar routes, and set up shared oversight of bills | completed | GL-ALZ-2024 | S |
| Caregiver support: education about mild cognitive impairment and PTSD, the Alzheimer's Association 24/7 Helpline (which serves all causes of cognitive impairment), a caregiver class and a burden check; the Medicare GUIDE model explained for if dementia develops later | completed | GL-ALZ-2024, GL-GUIDE | S |
| Advance care planning while he can take part fully: a health care agent, his values and goals of care, at the annual wellness visit | completed | GL-ALZ-2024, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Find the cause of the memory problems and explain it to him in a way he can take in | 2026-06-16 | completed | Mild cognitive impairment most likely due to traumatic brain injury; explained with his care partner present, at his request, with a written summary | S |
| A clinically meaningful fall in PTSD symptoms (PCL-5 down at least 10 points) by four months | 2026-09-15 | completed | PCL-5 from 41 to 26 after cognitive processing therapy and sertraline | S |
| Nightmares no more than about once a week, with at least six hours of sleep most nights | 2026-10-27 | completed | Nightmares about once every two weeks; sleeping about six and a half hours | S |
| No falls, with a balance and strength program | 2026-10-27 | completed | No falls; Timed Up and Go from 13 to 10 seconds after physical therapy and a home program | S |
| Name a health care agent and record his goals of care while he can take part fully | 2026-08-04 | completed | Health care agent named and goals of care recorded at the annual wellness visit | S |
Structured synthetic safety assessment on 2026-05-05: current ideation absent, intent absent, plan absent. Outpatient care with a collaborative safety plan, the 988 Suicide & Crisis Lifeline, medicines kept by his care partner, and a two-week follow-up; safety reviewed at every visit [S]